Vaccine Candidate Reduced Household Transmission of SARS-CoV-2

Clover Biopharmaceuticals, Ltd. and the International Vaccine Institute today announced that Clinical Infectious Diseases had published additional data from SPECTRA, a global Phase 2/3 clinical trial.

This new data showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

The study demonstrated that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 compared to households where the infected household member was not vaccinated.

Among the 134 household contacts of infected household members who had received SCB-2019, there was one case of COVID-19; among the 250 household contacts of infected household members who were not vaccinated, there were 12 cases.

“These results are important for public health officials striving to control future outbreaks and indicate that vaccination with SCB-2019 considerably reduces the risk of SARS-CoV-2 spreading within communities,” said Dr. Nicholas Jackson, President of Global Research and Development of Clover, in a related press release.

“The new data on community-level impact further strengthens our confidence in SCB-2019 as a premier vaccine that can potentially play an important role in large-scale vaccination campaigns in China and globally.”

This study was performed at eight Phase 2/3 SPECTRA sites in the Philippines. Enrolled households and household contacts were monitored for three weeks to detect new COVID-19 infections.

Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide.

Clover is working towards completing regulatory submissions to the China National Medical Products Administration, the European Medicines Agency, and the World Health Organization for SCB-2019 by the end of 2022.

While concurrently preparing for its commercialization in China and globally upon receiving regulatory approvals.